Posts by Raymond J. March
Raymond J. March is a Research Fellow and Director of FDAReview.org with the Independent Institute. He is also an Assistant Professor of Economics at Angelo State University where he is the Assistant Director of the Free Market Institute, Assistant Research Professor at Texas Tech University, Public Choice and Public Policy fellow with the American Institute for Economic Research, and an affiliated scholar with the Challey Institute for Global Innovation and Growth. His research has appeared in Health Economics, Southern Economic Journal, Public Choice, Research Policy, Food Policy, Journal of Institutional Economics, The Independent Review and other academic outlets. His popular articles have appeared in Fortune, Washington Examiner, National Interest, Washington Times, Sun Sentinel, The Hill, Real Clear Health, Medical News Daily. He earned his Ph.D. from Texas Tech University.
When is a Drug Safe and Effective Enough?
The FDA is Too Little Too Late in Tinkering with Covid-19 Booster Schedules
Deregulation Remains Our Best Hope to Combat Alzheimer’s Disease
Here Is How the FDA Made the RSV Wave More Dangerous
Why Does Dr. Fauci’s Replacement Matter So Much?
Mental Health Is in Crisis. What Is the Answer?
Three More Months of the Ratchet Effect?
Don’t Let the FDA Tell You What’s Healthy
Why Did it Take So Long for the US to Get the Novavax Vaccine?
Government COVID Blunders Continue With Monkeypox
Monkeypox and Leviathan?
My Thank You to David Theroux
Vaccines and Operation Warp Speed
OWS Gets Credit for the Vaccine, But Did We Need It?
Are EUAs Deregulation or Regulatory Capture?
Why Emergency Use Authorizations Should Stay
FDA Continues to Meddle with Covid-19 Treatments
The Covid-19 Ratchet Effect is Becoming Clearer, and More Concerning 
Will the Biden Administration Let a Delta-Variant Covid-19 Crisis Go to Waste? 
New Alzheimer’s Drug Approval Could Change the FDA’s Approval Process for the Better
Ecstasy Nears FDA Approval to Treat Severe Post-Traumatic Stress Disorder
AstraZeneca Vaccine Controversy Provides Another Example of Overly Cautious Government Reactions
Are We Witnessing the Beginning of the Covid-19 Ratchet Effect?
The FDA Should Grant Emergency Use Authorization for Alzheimer’s Drug
President Biden Faces Longstanding Challenge to Lower Insulin Prices. Will He Succeed?
Capping Insulin Copays Won’t Cure Insulin Price Woes
Early Covid-19 Vaccine Distribution Troubles Add to a Long List of Government Pandemic Failures

  • Catalyst
  • Beyond Homeless
  • MyGovCost.org
  • FDAReview.org
  • OnPower.org
  • elindependent.org